Antibody combo knocks down HIV in Clinical Trials

According to research, a mix of two monoclonal antibody against HIV has indicated a decrease in virus in patient not taking antiretroviral medication. However, this therapy has proven to be relatively expensive. In order to overcome the recurrence of HIV after the utilization of antiretroviral therapy, research mainly focuses on the administration of two monoclonal antibodies which target the envelope of the HIV virus. This has proven to provide relatively positive results in HIV patients allowing them to go off drugs for several months.